Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nycomed acquires Guangdong Techpool Bio-Pharma in China
The acquisition will allow Nycomed to gain access to a number of biologic and protein-based drugs manudactured by Techpool. Techpool has developed and launched a number of protein
The acquisition will allow Nycomed to gain access to a number of biologic and protein-based drugs manudactured by Techpool. Techpool has developed and launched a number of protein
Smith will replace Richard Friedman, who will be stepping down as CEO to serve as non-executive chairman of the BioScrip board of directors, effective 1 January 2011. Prior
Akorn has posted a net income of $3.99m for the third quarter 2010, or $0.04 per diluted share, compared to net loss of $5.1m, or $0.06 loss per
VGX-3100 is a therapeutic vaccine for cervical dysplasia and cancer. The grant will also support Inovio Pharma’s development projects for Syncon universal flu and dengue vaccines. The PPACA
Boehringer is expected to make available the 75mg dose of Pradaxa in pharmacies in the coming weeks. Pradaxa received approval from the US Food and Drug Administration (FDA)
The Talent Captivia System is indicated specifically for the endovascular repair of fusiform aneurysms and saccular aneurysms/penetrating ulcers of the descending thoracic aorta in patients having appropriate anatomy.
Beckley is expected to oversee LDM Group’s high-performance pharmacy and EMR teams, manage key initiatives, and develop sales and new business strategies for future growth opportunities in the
Seattle Genetics has posted a net loss of $34.86m for the third quarter 2010, or $0.34 loss per diluted share, compared to $19.83m, or $0.21 loss per diluted
Taribavirin and ribavirin are both nucleoside antimetabolite drugs that interfere with duplication of viral genetic material. As per the terms of the first agreement, Kadmon has got an
Parexel has posted a net income of $17.79m for the first quarter 2010, or $0.3 per diluted share, compared to $12.44m, or $0.21 per diluted share, for the